Author:
Zhou Zhaoxia,Guan Hengyong,Xiu Meihong,Wu Fengchun
Abstract
AbstractAccumulating evidence has supported the implementation of dance/movement therapy (DMT) as a promising intervention for patients with schizophrenia (SCZ). However, its effect on body weight and metabolic profile in SCZ remains unclear. This study aimed to evaluate the outcome of a 12-week DMT session on weight and lipid profile in patients with SCZ using a randomized, single-blinded, controlled trial design. This study encompassed two groups of long-term hospitalized patients with SCZ, who were randomly assigned to the DMT intervention (n = 30) or the treatment as usual (TAU) group (n = 30). Metabolic markers, including weight, body mass index (BMI), fasting glucose, triglycerides, and total cholesterol were measured in both groups at two measurement points (at baseline and the end of the 12-week treatment). We found that DMT intervention significantly decreased body weight (F = 5.5, p = 0.02) and BMI (F = 5.7, p = 0.02) as compared to the TAU group. However, no significance was observed in other metabolic markers, including fasting glucose, triglycerides, and total cholesterol after treatment (all p > 0.05). Our study indicates that a 12-week, 24-session DMT program may be effective in decreasing body weight and BMI in long-term hospitalized patients with SCZ. DMT intervention may be a promising treatment strategy for long-term inpatients in the psychiatric department.
Publisher
Springer Science and Business Media LLC
Reference64 articles.
1. Barnett, R. Schizophrenia. Lancet 391, 648 (2018).
2. Zhu, M. H. et al. Amisulpride augmentation therapy improves cognitive performance and psychopathology in clozapine-resistant treatment-refractory schizophrenia: a 12-week randomized, double-blind, placebo-controlled trial. Mil. Med. Res. 9, 59 (2022).
3. Li, S., Chen, D., Xiu, M., Li, J. & Zhang, X. Y. Diabetes mellitus, cognitive deficits and serum BDNF levels in chronic patients with schizophrenia: A case-control study. J. Psychiatr. Res. 134, 39–47 (2021).
4. Li, S. et al. T(4) and waist:hip ratio as biomarkers of antipsychotic-induced weight gain in Han Chinese inpatients with schizophrenia. Psychoneuroendocrinology 88, 54–60 (2018).
5. Li, S. et al. TOX and ADIPOQ Gene Polymorphisms are associated with antipsychotic-induced weight gain in Han Chinese. Sci. Rep. 7, 45203 (2017).